WASHINGTON--Sulindac, a non-steroidal anti-inflammatory drug (NSAID),
is known to prevent the growth of adenomas and cause their regression in
patients with familial adenomatous polyposis, but data are limited for
its effects in the more common sporadic adenomas.
Now, a study presented at Digestive Disease Week has shown that sulindac
may be an effective therapy for common polyps. "These findings have
great potential for polyp treatment and cancer prevention," said James
A. DiSario, MD, assistant professor of medicine, the University of Utah
Health Sciences Center.
The study included persons without familial syndromes who had polyps
identified at colonoscopy. A small polyp was marked and left in place.
Then, in a randomized double-blinded fashion, patients were assigned to
receive either sulindac or a placebo. Colonoscopy was repeated after a
year of treatment, and any polyps that remained in place were measured
In the sulindac group, 78% of patients had regression or stabilization
of their polyps. Compared with polyps in the control group, polyps in the
sulindac-treated patients shrank by 29%, and no polyp in the treatment